* Andrx Corp., of Fort Lauderdale, Fla., was awarded $100,000 underPhase I of a Small Business Technology Transfer grant fordevelopment of agents to limit the neutropenia associated with the useof AZT and other myelosuppresive antiretroviral agents.* Biorelease Corp., of Salem, N.H., said its hemoglobin-based cellculture additive Erythrogen, originally introduced for insect cells,completed evaluation in two mammalian cell lines and was shown toenhance cell visibility and protein production.* Carrington Laboratories Inc., of Irving, Texas, granted an exclusivelicense to Keun Wha Pharmaceuticals to manufacture and marketCarrasyn Hydrogel Wound dressing in the Republic of Korea. AndCarrington has begun sales in Puerto Rico, the Caribbean and LatinAmerica.* Corning Life Sciences Inc., a wholly owned subsidiary of CorningInc., and BioPro Corp. of Austin, Texas, are discussing the formationof a jointly owned company that would offer contract manufacturing ofnew biological products at a facility in Research Triangle Park, N.C.* Eli Lilly and Co., of Indianapolis, has completed its acquisition ofSphinx Pharmaceuticals Corp., paying $6 per share for the Durham,N.C.- based company. Sphinx will operate as a division of Lilly withfacilities in Durham and Cambridge, Mass.* Genus Communications Ltd. was launched in London as a investorand media relations consulting company for science-based companies.* GeriatRx Pharmaceutical Corp., of Vancouver, British Columbia,formerly Cangaurd Pharma Inc., consolidated its share capital on a 5-for-1 basis, and the consolidated shares will begin trading on theVancouver Stock Exchange under the symbol "GRX."* ID Biomedical Corp., of Vancouver, British Columbia, signed aresearch agreement with bioMerieux Vitek Inc. to evaluate IDB'sScissile Linkage and Cycling Probe technologies with one ofbioMerieux's automated instrument systems.* Intergen Co., of Purchase, N.Y., said it has completed a successfulvirus validation study for its bovine serum albumins productionprocess. The company said recently completed experimentsdemonstrated clearance of all viruses during manufacture of Intergen'sBovuminar bovine serum albumins.* InterPharm Laboratories Ltd., of Israel, filed an action for damages of$3.6 million against 41 minority shareholders, who own less than 5percent of the company, and who InterPharm said is disruptingbusiness in order to extract a higher price from Ares-Serono A.G. in itsbuyout effort.* Oncogene Science Inc., of Uniondale, N.Y., said its collaborativepartner, Ciba-Geigy Ltd., started a Phase I trial of its recombinanttransforming growth factor beta 3 for treatment of chronic skinwounds. The first trial results are expected by the end of October.* PerSeptive Biosystems Inc., of Cambridge, Mass., has begunmarketing its Integral micro-analytical workstation for biomolecularcharacterization and analysis. Integral is an instrument that combinesthe company's Perfusion Chromatography and ImmunoDetectiontechnologies.* SangStat Medical Corp., of Menlo Park, Calif., has filed a new drugsubmission in Canada to market Thymoglobulin for prevention of solidorgan transplant rejection. The company licensed rights to develop andmarket the drug, a rabbit anti-thymocyte globulin, in the U.S. andCanada from Rhone-Poulenc Group, of Paris. SangStat is conducting aPhase III clinical trial of Thymoglobulin in the U.S. Rhone-Poulenc'ssubsidiary, Pasteur Merieux Serums et Vaccins, currently markets thedrug in 26 countries outside North America.* Signal Pharmaceuticals Inc., of San Diego, was awarded a $100,000Phase I Small Business Technology Transfer grant to develop humanneuronal cell lines for use in screening drug candidates.* TheraTech Inc., of Salt Lake City, has secured a $6 million, 15-yearmortgage to cover the cost of its recently constructed 63,000-square-foot manufacturing plant adjacent to the company's corporateheadquarters. TheraTech is involved in the development of controlledrelease drug delivery systems, such as transdermal patches and oraltransmucosal products.* ZymoGenetics Inc., a subsidiary of Denmark-based Novo NordiskAopened its new headquarters in a 113,000-square-foot facility inSeattle.
(c) 1997 American Health Consultants. All rights reserved.